Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-202 in Metabolic Syndrome
NCT05282446Phase 1Completed
- Sponsor
- Inversago
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic syndrome comparing INV-202 with Placebo (2 arms). Primary endpoint: Number and Frequency of Adverse Events at 28 Days. Started Mar 2022; status: completed.
02
Drugs
monlunabant
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT05282446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282446.